Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 16/20 | 1.00 |
| ▸ | CCND1 | P24385 | 16/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 9/20 | 1.00 |
| ▸ | CCND3 | P30281 | 3/20 | 0.98 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.98 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.98 |
| ▸ | CDK9 | P50750 | 2/20 | 0.98 |
| ▸ | TTK | P33981 | 1/20 | 0.82 |
| ▸ | FLT3 | P36888 | 1/20 | 0.82 |
| ▸ | CCNH | P51946 | 1/20 | 0.82 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.82 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.82 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trilaciclib SCHEMBL29763763 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL10082028 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29356370 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29375833 | 0.98 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29514690 | 0.98 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20959535 | 0.93 | CDK2 (0.86) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL10082029 | 0.92 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551643 | 0.92 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22005339 | 0.91 | CDK2 (0.84) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL15249273 | 0.91 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-8822683-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142306-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142299-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CDK2 5/4885CDK4 12/4885CCND1 47/4885 |
| US-20230364098-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | CDK2 13/4885CDK4 2/4885CCND1 84/4885 |
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | CDK2 69/4885CDK4 16/4885CCND1 36/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | CDK2 10/4885CDK4 6/4885CCND1 41/4885 |
| US-20140142306-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | CDK2 5/4885CDK4 12/4885CCND1 47/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | CDK2 16/4885CDK4 1/4885CCND1 47/4885 |
| US-20140142299-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | CDK2 5/4885CDK4 12/4885CCND1 47/4885 |
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | CDK2 10/4885CDK4 6/4885CCND1 41/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CDK2 5/4885CDK4 12/4885CCND1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.